Roman Butler Fullerton & Co. Invests $1.02 Million in Merck & Co., Inc. (NYSE:MRK) Stock

Roman Butler Fullerton & Co. bought a new stake in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 13,736 shares of the company’s stock, valued at approximately $1,023,000. Merck & Co., Inc. comprises 0.9% of Roman Butler Fullerton & Co.’s investment portfolio, making the stock its 27th biggest position.

Other institutional investors and hedge funds have also bought and sold shares of the company. Chase Investment Counsel Corp lifted its holdings in shares of Merck & Co., Inc. by 687.4% in the 4th quarter. Chase Investment Counsel Corp now owns 46,715 shares of the company’s stock valued at $3,569,000 after buying an additional 40,782 shares during the period. BHK Investment Advisors LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth $211,000. Dearborn Partners LLC raised its holdings in Merck & Co., Inc. by 1.2% during the fourth quarter. Dearborn Partners LLC now owns 257,257 shares of the company’s stock worth $19,657,000 after purchasing an additional 3,143 shares during the last quarter. SeaBridge Investment Advisors LLC raised its holdings in Merck & Co., Inc. by 10.5% during the fourth quarter. SeaBridge Investment Advisors LLC now owns 37,881 shares of the company’s stock worth $2,894,000 after purchasing an additional 3,592 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC raised its holdings in Merck & Co., Inc. by 15.9% during the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 2,473 shares of the company’s stock worth $189,000 after purchasing an additional 340 shares during the last quarter. 73.39% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Robert M. Davis sold 192,572 shares of the company’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $82.38, for a total transaction of $15,864,081.36. Following the completion of the transaction, the executive vice president now directly owns 330,232 shares of the company’s stock, valued at $27,204,512.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas H. Glocer sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 4th. The shares were sold at an average price of $75.96, for a total value of $759,600.00. The disclosure for this sale can be found here. Insiders have sold 1,094,632 shares of company stock valued at $87,840,652 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

MRK has been the subject of a number of analyst reports. Morgan Stanley set a $81.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, December 20th. Citigroup set a $65.00 price objective on Merck & Co., Inc. and gave the company a “hold” rating in a research report on Thursday, December 20th. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 price objective for the company in a research report on Friday, January 4th. BMO Capital Markets downgraded Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price target for the company. in a research report on Wednesday, January 23rd. Finally, Argus boosted their price target on Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 20th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $77.83.

NYSE:MRK opened at $78.53 on Tuesday. Merck & Co., Inc. has a one year low of $56.26 and a one year high of $83.85. The stock has a market capitalization of $214.16 billion, a P/E ratio of 18.09, a price-to-earnings-growth ratio of 1.94 and a beta of 0.63. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.17.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 1st. The company reported $1.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a return on equity of 36.83% and a net margin of 14.71%. The firm had revenue of $11 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the firm posted $0.98 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, equities research analysts predict that Merck & Co., Inc. will post 4.65 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, April 5th. Stockholders of record on Friday, March 15th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.80%. The ex-dividend date of this dividend was Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

COPYRIGHT VIOLATION NOTICE: “Roman Butler Fullerton & Co. Invests $1.02 Million in Merck & Co., Inc. (NYSE:MRK) Stock” was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/16/roman-butler-fullerton-co-takes-1-02-million-position-in-merck-co-inc-mrk.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Stock Symbols and CUSIP Explained

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.